Physician profile
Michael Lagoe
NPI 1730698044
$14,604.76
in general payments reported to CMS, 2019-2025
46 companies · $4,134 in 2025
The $4,134 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $2,268 · 2023: $3,528 · 2024: $4,501 · 2025: $4,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $980 · Education: $10.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,171.71 |
| Consulting Fee | $980.00 |
| Education | $10.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,819.47 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $1,593.99 | 2022-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $1,574.37 | 2022-2025 | Crexont, Rytary, Ongentys |
| Mdd US Operations, LLC | $1,158.77 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Acadia Pharmaceuticals INC | $1,099.66 | 2022-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $920.24 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $768.22 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $629.27 | 2023-2025 | |
| Eisai INC. | $406.71 | 2023-2025 | |
| Ge Healthcare | $364.72 | 2022-2025 | |
| Tanabe Pharma America, INC. | $358.93 | 2022-2025 | Radicava |
| Kyowa Kirin, INC. | $256.33 | 2022-2024 | Nourianz |
| Biogen, INC. | $231.68 | 2021-2025 | Leqembi, Skyclarys |
| Acorda Therapeutics, INC | $230.56 | 2022-2024 | Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $197.94 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $189.52 | 2024-2025 | Nayzilam, Rystiggo |
| Lundbeck LLC | $189.36 | 2024-2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $188.08 | 2023-2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $160.24 | 2022-2025 | Xeomin, Inbrija |
| Amgen INC. | $134.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $115.41 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $98.97 | 2024-2025 | Hyqvia |
| Corium, LLC | $97.57 | 2022-2023 | Adlarity |
| Scilex Pharmaceuticals INC. | $92.90 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $82.82 | 2022 | |
| Grt US Holding, INC. | $72.62 | 2021-2022 | |
| Medtronic, INC. | $70.56 | 2023-2025 | Percept PC Brainsense, Activa PC |
| Collegium Pharmaceutical, INC. | $55.99 | 2021 | |
| Revance Therapeutics, INC. | $55.53 | 2024-2025 | Daxxify |
| Boston Scientific Corporation | $48.15 | 2023-2025 | General - Dbs |
| Avion Pharmaceuticals | $33.44 | 2022 | |
| Cala Health, INC. | $29.21 | 2025 | Cala Kiq |
| Genentech USA, INC. | $28.31 | 2024 | Evrysdi |
| Currax Pharmaceuticals LLC | $26.22 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.00 | 2025 | Ultomiris |
| Grifols USA, LLC | $23.09 | 2024 | Gamunex-C |
| C2n Diagnostics, LLC | $22.70 | 2025 | Precivityad2 |
| Csl Behring | $22.08 | 2022 | |
| Argenx US, INC. | $21.99 | 2025 | Vyvgart Hytrulo |
| Abbott Laboratories | $19.79 | 2024 | Eterna |
| Azurity Pharmaceuticals, INC. | $16.88 | 2025 | Horizant |
| Impel Pharmaceuticals LLC | $15.96 | 2025 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $15.88 | 2021 | |
| Hikma Pharmaceuticals USA | $15.34 | 2022 | |
| Redhill Biopharma INC. | $14.29 | 2021 | |
| Ibsa Pharma INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lagoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.